{"title":"[无法切除的局部晚期食管鳞状细胞癌化疗后长期存活病例]","authors":"Satoru Matono, Takafumi Ohchi, Sho Setojima, Atsushi Kaibara, Naoki Mori, Kohei Saisho, Masashi Nakagawa, Haruhiro Hino, Nobuya Ishibashi, Toshiaki Tanaka, Fumihiko Fujita, Etsuyo Ogo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>67-year-old woman underwent definitive chemoradiotherapy( dCRT) with cisplatin( CDDP) and 5-fluorouraci(l 5-FU)(FP) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus. During treatment, the patient developed grade 3 pharyngitis and esophagitis as adverse events. She was administered maintenance chemotherapy with 2 courses of FP and achieved complete response. Currently, she experiences esophageal stenosis; however, she remains alive and recurrence-free 9 years after initial treatment. While dCRT is effective for locally advanced esophageal cancer, its adverse effects may persist. Herein, we report our case and have included relevant literature considerations.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1161-1164"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Case of Long-Term Survival after Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma].\",\"authors\":\"Satoru Matono, Takafumi Ohchi, Sho Setojima, Atsushi Kaibara, Naoki Mori, Kohei Saisho, Masashi Nakagawa, Haruhiro Hino, Nobuya Ishibashi, Toshiaki Tanaka, Fumihiko Fujita, Etsuyo Ogo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>67-year-old woman underwent definitive chemoradiotherapy( dCRT) with cisplatin( CDDP) and 5-fluorouraci(l 5-FU)(FP) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus. During treatment, the patient developed grade 3 pharyngitis and esophagitis as adverse events. She was administered maintenance chemotherapy with 2 courses of FP and achieved complete response. Currently, she experiences esophageal stenosis; however, she remains alive and recurrence-free 9 years after initial treatment. While dCRT is effective for locally advanced esophageal cancer, its adverse effects may persist. Herein, we report our case and have included relevant literature considerations.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"51 11\",\"pages\":\"1161-1164\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Case of Long-Term Survival after Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma].
67-year-old woman underwent definitive chemoradiotherapy( dCRT) with cisplatin( CDDP) and 5-fluorouraci(l 5-FU)(FP) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus. During treatment, the patient developed grade 3 pharyngitis and esophagitis as adverse events. She was administered maintenance chemotherapy with 2 courses of FP and achieved complete response. Currently, she experiences esophageal stenosis; however, she remains alive and recurrence-free 9 years after initial treatment. While dCRT is effective for locally advanced esophageal cancer, its adverse effects may persist. Herein, we report our case and have included relevant literature considerations.